Malaria Parasite Sexual Development, Drug Resistance, and Evolution

疟疾寄生虫的性发育、耐药性和进化

基本信息

项目摘要

We have finished collecting single nucleotide polymorphisms (SNPs) from 3539 genes on all of the 14 chromosomes of Plasmodium falciparum, leading to a publication in Nature Genetics early this year. In addition to developing genome-wide SNP map, our study also identified many candidate molecules that could be under host immune selection (antigens). Based on the SNPs identified, we have developed a microarray platform (Molecular Inversion Probe or PArAllele) that allows us to genotype large numbers of SNPs in a single hybridization. Parasites are being collected from patients at our clinical field site in Cambodia. Many of the parasites have been adapted and grown in in vitro culture. DNA samples from the parasites are being prepared for hybridization. We also have been evaluating a high-density microarray with 2.5 million probes for genotyping and other studies. Our data suggested that this high-density array could be a good alternative for SNP typing. The parasite responses to different antimalarial drugs are being tested to identify mutations potentially contributing to drug resistances. Another project we are working on is ABC transporters and their roles in drug resistance in P. falaciprum. We have genetically knockout one of the ABC transporters associated with chloroquine and quinine resistances in our pervious study and are evaluating the effects of gene knockout on parasite drug responses. We have finished the data analyses of our ESTcDNA collection. Our data showed considerable gene prediction inaccuracy in the P. falciparum. In collaboration with scientists in Mexico, we have also been studying Plasmodium vivax populations and their host specificity in Southern Mexico. Our data showed that P. vivax population there could be divided into three populations that were transmitted by two different mosquito species with different efficiency. This study can potentially provide information for better understanding of the molecular mechanisms of parasite and host interaction (or host specificity). We are still interested in various aspects of parasite sexual development, particularly the biological functions of Pfmdv1 and other genes that may involve in the process of gametocyte development.
我们已经完成了从恶性疟原虫所有14条染色体上的3539个基因中收集单核苷酸多态性(SNP)的工作,并于今年早些时候在《自然遗传学》上发表了论文。除了建立全基因组SNP图谱外,我们的研究还确定了许多可能受到宿主免疫选择的候选分子(抗原)。基于所鉴定的SNPs,我们开发了一种微阵列平台(分子倒置探针或PArAllele),该平台允许我们在单次杂交中对大量SNPs进行基因分型。我们正在柬埔寨的临床现场从患者身上收集寄生虫。许多寄生虫已经适应并在体外培养中生长。寄生虫的DNA样本正在准备用于杂交。我们也一直在评估一个高密度微阵列与250万探针的基因分型和其他研究。我们的数据表明,这种高密度阵列可能是SNP分型的良好替代方案。正在测试寄生虫对不同抗疟药物的反应,以确定可能导致抗药性的突变。 我们正在研究的另一个项目是ABC转运蛋白及其在恶性疟原虫耐药性中的作用。在我们先前的研究中,我们已经从基因上敲除了与氯喹和奎宁抗性相关的ABC转运蛋白之一,并正在评估基因敲除对寄生虫药物反应的影响。 我们已经完成了我们的ESTcDNA收集的数据分析。我们的数据显示恶性疟原虫中相当大的基因预测不准确。 我们还与墨西哥的科学家合作,研究了墨西哥南部的间日疟原虫种群及其宿主特异性。结果表明,该地区间日疟原虫可分为3个种群,由两种不同蚊种传播,传播效率不同。本研究为深入了解寄生虫与宿主相互作用的分子机制(或宿主特异性)提供了信息。 我们仍然对寄生虫性发育的各个方面感兴趣,特别是Pfmdv1和其他可能参与配子体发育过程的基因的生物学功能。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Xinzhuan Su其他文献

Xinzhuan Su的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Xinzhuan Su', 18)}}的其他基金

Malaria Parasite Development, Drug Resistance, and Genomics
疟疾寄生虫的发育、耐药性和基因组学
  • 批准号:
    8336151
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Sexual Development, Drug Resistance, and Evolution
疟疾寄生虫的性发育、耐药性和进化
  • 批准号:
    7732562
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Development, Drug Resistance, Pathogenesis, and Genomics
疟疾寄生虫的发育、耐药性、发病机制和基因组学
  • 批准号:
    8946351
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Genomic/Genetic Approach To Malaria Parasite Development
疟疾寄生虫发育的基因组/遗传学方法
  • 批准号:
    6507113
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Sexual Development, Drug Resistance, an
疟原虫性发育、耐药性、
  • 批准号:
    7303881
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Sexual Development and Drug Resistance
疟疾寄生虫的性发育和耐药性
  • 批准号:
    7196685
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Sexual Development, Drug Resistance, an
疟原虫性发育、耐药性、
  • 批准号:
    6669897
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Development, Drug Resistance, and Genomics
疟疾寄生虫的发育、耐药性和基因组学
  • 批准号:
    8555855
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Development, Drug Resistance, Pathogenesis, and Genomics
疟疾寄生虫的发育、耐药性、发病机制和基因组学
  • 批准号:
    9563887
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:
Malaria Parasite Development, Drug Resistance, Pathogenesis, and Genomics
疟疾寄生虫的发育、耐药性、发病机制和基因组学
  • 批准号:
    10014086
  • 财政年份:
  • 资助金额:
    $ 136.96万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 136.96万
  • 项目类别:
    Research Grant
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
    Operating Grants
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
    Small Business Research Initiative
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 136.96万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了